HAMP and cystic fibrosis: Regardless of ex vivo modulator pretreatment, we found that prescribed modulator use in vivo coincided with a trend in lower hepcidin secretion in LPS-activated CF MDMs compared to LPS-activated CF MDMs from patients who did not use in vivo modulators (Supplementary Fig. S3e).